<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625426</url>
  </required_header>
  <id_info>
    <org_study_id>SIG18037</org_study_id>
    <nct_id>NCT04625426</nct_id>
  </id_info>
  <brief_title>Evaluation of Skin Cleansers and Skin Protectants in Management of Incontinence-associated Dermatitis</brief_title>
  <official_title>Evaluate the Efficacy of Two Advanced Skin Treatment Regimens in Treating Incontinence-associated Dermatitis: Cluster Randomization Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of two different skin care regimens (3M&#xD;
      Cavilon Advanced Skin Protectant with 3M No-Rinse Cleanser and Coloplast Conveen Critic&#xD;
      Barrier with Easi-Cleanser) against standard care (Skin wipes and Conveen Critic Barrier) in&#xD;
      the management of Incontinence-Associated Dermatitis (IAD) in hospitalised patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the efficacy of two different skin care regimens (3M&#xD;
      Cavilon Advanced Skin Protectant with 3M No-Rinse Cleanser and Coloplast Conveen Critic&#xD;
      Barrier with Easi-Cleanser) against standard care (Skin wipes and Conveen Critic Barrier) in&#xD;
      the management of Incontinence-Associated Dermatitis (IAD) in hospitalised patients.&#xD;
&#xD;
      To date, there is no conclusive evidence on the &quot;best treatment&quot; for patients presenting with&#xD;
      IAD. This has led to current clinical practices tend to select IAD products based on its cost&#xD;
      and availability, which can be heavily influenced by marketing and commercialisation efforts.&#xD;
&#xD;
      This study allows investigation of the effectiveness of IAD products to ensure the provision&#xD;
      of optimal care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination due to COVID-19 pandemic led to inability to reach planned sample size&#xD;
  </why_stopped>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cluster randomised trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced IAD Healing</measure>
    <time_frame>Up to seven days from initiation of treatment</time_frame>
    <description>Total number of participants who experienced IAD healing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants With IAD Healing</measure>
    <time_frame>Up to seven days from initiation of treatment</time_frame>
    <description>Percentage of participants who experienced IAD healing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Skin Loss</measure>
    <time_frame>Up to three days from initiation of treatment</time_frame>
    <description>Examination of the development of skin loss using the Ghent Global IAD Categorisation tool (GLOBIAD).&#xD;
Binary scoring, 1 and 2. Higher value (2) indicates worse outcome (Development of skin loss)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Incontinence-associated Dermatitis</condition>
  <arm_group>
    <arm_group_label>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conveen EasiCleanse and Conveen Critic Barrier</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soap and water / Incontinence wipes and Conveen Critic Barrier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant</intervention_name>
    <description>Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
    <arm_group_label>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conveen EasiCleanse and Conveen Critic Barrier</intervention_name>
    <description>Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
    <arm_group_label>Conveen EasiCleanse and Conveen Critic Barrier</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard cleansing and Conveen Critic Barrier</intervention_name>
    <description>Hospital's standard care for IAD management</description>
    <arm_group_label>Soap and water / Incontinence wipes and Conveen Critic Barrier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 21 years and above at point of recruitment&#xD;
&#xD;
          -  Diagnosed with IAD&#xD;
&#xD;
          -  At regular risk of exposure to urine and faeces over their hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a known allergy to the treatment products&#xD;
&#xD;
          -  Haemodynamically unstable at point of assessment for study&#xD;
&#xD;
          -  Unable to tolerate lateral positioning for skin cleansing and treatment application&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Having an existing skin disease at point of study that might lead to inaccurate IAD&#xD;
             assessment, such as herpes or scabies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ee Yuee Chan</last_name>
    <role>Study Director</role>
    <affiliation>Tan Tock Seng Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng Cheng Goh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tan Tock Seng Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Beeckman D, Van Damme N, Schoonhoven L, Van Lancker A, Kottner J, Beele H, Gray M, Woodward S, Fader M, Van den Bussche K, Van Hecke A, De Meyer D, Verhaeghe S. Interventions for preventing and treating incontinence-associated dermatitis in adults. Cochrane Database Syst Rev. 2016 Nov 10;11:CD011627. Review.</citation>
    <PMID>27841440</PMID>
  </reference>
  <reference>
    <citation>Van Tiggelen H, LeBlanc K, Campbell K, Woo K, Baranoski S, Chang YY, Dunk AM, Gloeckner M, Hevia H, Holloway S, Idensohn P, Karadağ A, Koren E, Kottner J, Langemo D, Ousey K, Pokorná A, Romanelli M, Santos VLCG, Smet S, Tariq G, Van den Bussche K, Van Hecke A, Verhaeghe S, Vuagnat H, Williams A, Beeckman D. Standardizing the classification of skin tears: validity and reliability testing of the International Skin Tear Advisory Panel Classification System in 44 countries. Br J Dermatol. 2020 Jul;183(1):146-154. doi: 10.1111/bjd.18604. Epub 2019 Nov 28.</citation>
    <PMID>31605618</PMID>
  </reference>
  <reference>
    <citation>Beele H, Smet S, Van Damme N, Beeckman D. Incontinence-Associated Dermatitis: Pathogenesis, Contributing Factors, Prevention and Management Options. Drugs Aging. 2018 Jan;35(1):1-10. doi: 10.1007/s40266-017-0507-1. Review.</citation>
    <PMID>29243033</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <results_first_submitted>March 15, 2021</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2021</results_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04625426/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 participants initially recruited were found to be not eligible before being assigned to an arm, leading to them being dropped from the study before assignation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
          <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
        </group>
        <group group_id="P2">
          <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
          <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
        </group>
        <group group_id="P3">
          <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
          <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
          <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
        </group>
        <group group_id="B2">
          <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
          <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
        </group>
        <group group_id="B3">
          <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
          <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.2" spread="10.6"/>
                    <measurement group_id="B2" value="80.2" spread="9.56"/>
                    <measurement group_id="B3" value="80.7" spread="8.03"/>
                    <measurement group_id="B4" value="79.51" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="3.81"/>
                    <measurement group_id="B2" value="21.0" spread="5.19"/>
                    <measurement group_id="B3" value="20.4" spread="3.42"/>
                    <measurement group_id="B4" value="20.6" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of incontinence</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urinary incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Faecal incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dual incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Faecal frequency</title>
          <units>episodes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25" spread="1.65"/>
                    <measurement group_id="B2" value="3.52" spread="2.01"/>
                    <measurement group_id="B3" value="3.43" spread="2.31"/>
                    <measurement group_id="B4" value="3.43" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of indwelling urinary catheter</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool consistency</title>
          <description>Stool consistency measured using Bristol Stool Chart. The chart grades stool by 7 types Types 3 and 4 are ideal, reflecting smooth,easy-to-pass stool Types 1 and 2 are not ideal as they indicate diarrhoea Types 5, 6 and 7 are not ideal as they indicate diarrhoea Type 1: Separate hard lumps, hard to pass Type 2: Separate hard lumps, hard to pass Type 3, Type 4: Ideal stool consistency, smooth Type 5: Soft blobs with clear-cut edges Type 6: Mushy, fluffy stool Type 7: Watery, entirely liquid</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type 4 (Best Outcome)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5 (Second-best)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 6 (Third-best outcome)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 7 (Worst outcome)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced IAD Healing</title>
        <description>Total number of participants who experienced IAD healing</description>
        <time_frame>Up to seven days from initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
            <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
          </group>
          <group group_id="O2">
            <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
            <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
          </group>
          <group group_id="O3">
            <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
            <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced IAD Healing</title>
          <description>Total number of participants who experienced IAD healing</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Healed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Censored</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With IAD Healing</title>
        <description>Percentage of participants who experienced IAD healing</description>
        <time_frame>Up to seven days from initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
            <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
          </group>
          <group group_id="O2">
            <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
            <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
          </group>
          <group group_id="O3">
            <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
            <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With IAD Healing</title>
          <description>Percentage of participants who experienced IAD healing</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Skin Loss</title>
        <description>Examination of the development of skin loss using the Ghent Global IAD Categorisation tool (GLOBIAD).&#xD;
Binary scoring, 1 and 2. Higher value (2) indicates worse outcome (Development of skin loss)</description>
        <time_frame>Up to three days from initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
            <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
          </group>
          <group group_id="O2">
            <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
            <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
          </group>
          <group group_id="O3">
            <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
            <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Skin Loss</title>
          <description>Examination of the development of skin loss using the Ghent Global IAD Categorisation tool (GLOBIAD).&#xD;
Binary scoring, 1 and 2. Higher value (2) indicates worse outcome (Development of skin loss)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse data not collected over study period. This is because the interventions were assessed to have minimal risk of harm on participants.</time_frame>
      <desc>All-Cause Mortality, Serious and Other [Not Including Serious] Adverse Events were not monitored/assessed as interventions were assessed to have minimal risk of harm on participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant</title>
          <description>Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).&#xD;
The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer.&#xD;
3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant</description>
        </group>
        <group group_id="E2">
          <title>Conveen EasiCleanse and Conveen Critic Barrier</title>
          <description>Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.&#xD;
Conveen EasiCleanse and Conveen Critic Barrier: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream</description>
        </group>
        <group group_id="E3">
          <title>Soap and Water / Incontinence Wipes and Conveen Critic Barrier</title>
          <description>Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.&#xD;
Standard cleansing and Conveen Critic Barrier: Hospital's standard care for IAD management</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to COVID-19 pandemic led to inability to reach planned sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>George Glass, Nurse Researcher</name_or_title>
      <organization>Tan Tock Seng Hospital</organization>
      <phone>+65 6903-5440</phone>
      <email>glass_george_frederick@ttsh.com.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

